Swiss Tropical and Public Health Institute (Swiss TPH)

Research focus:

The Department of Medicines Research (MedRes) contributes to the research & development- and implementation process for drugs, vaccines and public health interventions. It conducts research and provides services in the collection of fundamental epidemiologic data, regulatory clinical trials, improvement of trial related quality management systems and contributes to procedures which allow access to new medicinal interventions. Health technology and telemedicine Unit (HTTU) focuses among else on HTA. We have been mandated to represent BAG/ SNHTA in various working groups of the European Network for Health Technology Assessment (EUnetHTA); in particular in the area of capacity building, training and organisational development with regards to HTA.  In various mandates, HTTU was entrusted to support HTA development in Europe (e.g. Romania, Czech Republic).

Health systems support Unit (SYSU): We conduct economic evaluation of the comparative costs and benefits of competing health care interventions and provide evidence to policy makers and service providers for making cost-effective decisions on resource allocation. We work with the WHO on resource planning and costing tools for which we provide training and technical support in costing health interventions. We have particular expertise in the area of vaccinations cost-effectiveness and implement numerous mandates from both the public and private sector.

 

Cooperation and networking:

Swiss Network of Health Technology Assessment (SNHTA, European Network for Health Technology Assessment (EUnetHTA), the Grading of Recommendations Assessment, Development and Evaluation (GRADE).

 

Publications (full publication record: http://www.swisstph.ch/research.html)

  • Bosch-Capblanch X, Lavis J, Lewin S, Atun R, Røttingen JA, Dröschel D, Beck L, Abalos E, El-Jardali F,Gilson L, Oliver S, Wyss K, Tugwell P, Regina Kulier, Pang T, Haines A. 2012. Guidance for evidence-informed decisions about health systems (I): rationale for and challenges of guidance development. PLoS Medicine 9(3): e1001185. doi:10.1371/journal.pmed.1001185.
  • Conteh L, Sicuri E, Manzi F, Hutton G, Obonyo B, et al. (2010) The Cost-Effectiveness of Intermittent Preventive Treatment for Malaria in Infants in Sub-Saharan Africa. PLoS ONE 5(6): e10313. doi:10.1371/journal.pone.0010313
  • Hanlon, P. et al 2011 Study Report: Health Economic Model for Employee Wellbeing Programme Ghana, Operational Public Health Research Project for GIZ Ghana. www.hespa.net
  • Kuemmerle A, Dodoo ANO, Olsson S, J. Van Erps, C. Burri, P. S. Lalvani (2011) Assessment of global reporting of adverse drug reactions for antimalarials, including Artemisinin-based Combination Therapies (ACTs), to the WHO Programme for International Drug Monitoring, Malaria Journal doi:10.1186/1475-2875-10-57
  • Küpfer I, C. Schmid, M. Allan, A. Edielu, EP. Haary, A. Kakembo, S. Kibona, J. Blum & C. Burri (2012) Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage rhodesiense sleeping sickness. PLoS Negl Trop Dis 6, e1695.
  • Probst-Hensch N, M Tanner, C. Kessler, C. Burri, N. Künzli (2011) Prevention – a cost-effective way to fight the non-communicable disease epidemic. Swiss Med Wkly. 2011;141:w13266.
  • Raab M, T. Dolecal (2012), HTA capacity building in Czech Republic. Policy document and training strategy. Conference papers in the frame of Czech – Swiss symposia
  • Zahorka M, M. Raab, N.Fota (2013), HTA curriculum development and HTA capacity building strategy for Romania (Policy paper for Romanian Ministry of Health and World Bank)